| Project/Area Number |
15K18915
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 腎移植 / 移植免疫 / ドナー特異的抗HLA抗体 / 免疫抑制剤 / 薬物治療モニタリング / 個別化医療 / 治療薬物モニタリング / 抗HLA抗体 |
|---|
| Outline of Final Research Achievements |
One of the major factors for the graft loss is antibody-mediated rejection caused by the production of donor-specific HLA antibody (DSA). In this study, we evaluated the influence of DSA in graft survival and the relation of clinical variants including immunosuppressant levels to the prediction of DSA production in post-renal transplantation. As a result, DSA production was observed in 15 patients including 7 preformed DSA, 6 de novo DSA and 1 both preformed+de novo DSA out of 180 patients. It was exhibited that all DSA are poor prognostic factors, and De novo DSA production was more likely to observed in patients who experienced the low serum Tac level (cut-off value: 3.2 ng/mL), and in patients who ceased MMF medication within one-year post-transplantation.
|
